GLP-1 inhibits glucagon release, which is a hormone that raises blood sugar levels. GLP-1 prolongs gastric emptying and leads ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize ...

GIP (red),  glucagon (violet) and PYY (green). Each hormone targets its own receptor. The effect of each receptor on the body are indicated using the same color code. The tetra-agonist compound ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials ...

Four clinical organizations jointly release an advisory with evidence-based nutrition and lifestyle interventions to enhance ...

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is), dipeptidyl peptidase‐4 inhibitors (DPP4Is), and glucagon‐like peptide‐1 receptor agonists have been associated with improved cardiovascular ...